Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sanofi Asks Thailand To Review Compulsory Licensing Policy

This article was originally published in PharmAsia News

Executive Summary

Sanofi-Aventis sent a request to the previous Thai Minister of Commerce Mingkwan Sangsuwan to review the process of compulsory licensing on patented drugs, Graham Almond, Sanofi-Aventis Thailand general manager told PharmAsia News.

You may also be interested in...



Thailand Probes Compulsory License Clopidogrel Purchasing Woes

Thailand’s Government Pharmaceutical Organization has faced heat from the health ministry over its attempts to buy blood thinner clopidogrel under a compulsory license issued for Sanofi’s Plavix in 2007. The issue is at the heart of the country’s attempts to provide universal health care without costs spiraling out of control.

Thailand Probes Compulsory License Clopidogrel Purchasing Woes

Thailand’s Government Pharmaceutical Organization has faced heat from the health ministry over its attempts to buy blood thinner clopidogrel under a compulsory license issued for Sanofi’s Plavix in 2007. The issue is at the heart of the country’s attempts to provide universal health care without costs spiraling out of control.

Is Sobering Tone On India IP Laws An Early Signal Of Reconciliation By U.S.?

Some lawyers say views on India’s patent laws may be softening despite India winding up again on the U.S. Priority Watch List.

Related Content

UsernamePublicRestriction

Register

OM004559

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel